Co-Authors
This is a "connection" page, showing publications co-authored by Michal Mandelboim and Ella Mendelson.
Connection Strength
2.755
-
Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. Euro Surveill. 2021 07; 26(26).
Score: 0.238
-
Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2. N Engl J Med. 2021 06 24; 384(25):2453-2454.
Score: 0.235
-
Genomic variation and epidemiology of SARS-CoV-2 importation and early circulation in Israel. PLoS One. 2021; 16(3):e0243265.
Score: 0.234
-
Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells. PLoS One. 2021; 16(2):e0247128.
Score: 0.233
-
Comprehensive Analyses of SARS-CoV-2 Transmission in a Public Health Virology Laboratory. Viruses. 2020 08 05; 12(8).
Score: 0.224
-
Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1. Viruses. 2018 09 21; 10(10).
Score: 0.197
-
Forty five percent of the Israeli population were infected with the influenza B Victoria virus during the winter season 2015-16. Oncotarget. 2018 Jan 19; 9(5):6623-6629.
Score: 0.187
-
Genetic divergence of Influenza A(H3N2) amino acid substitutions mark the beginning of the 2016-2017 winter season in Israel. J Clin Virol. 2017 08; 93:71-75.
Score: 0.180
-
A(H1N1)pdm09 influenza infection: vaccine inefficiency. Oncotarget. 2017 May 16; 8(20):32856-32863.
Score: 0.179
-
Influenza A(H1N1)pdm 2009 and influenza B virus co-infection in hospitalized and non-hospitalized patients during the 2015-2016 epidemic season in Israel. J Clin Virol. 2017 03; 88:12-16.
Score: 0.175
-
The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants. Cell Rep. 2021 09 07; 36(10):109679.
Score: 0.060
-
Sensitive Immunodetection of Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern 501Y.V2 and 501Y.V1. J Infect Dis. 2021 08 16; 224(4):616-619.
Score: 0.060
-
Prolonged detection of complete viral genomes demonstrated by SARS-CoV-2 sequencing of serial respiratory specimens. PLoS One. 2021; 16(8):e0255691.
Score: 0.060
-
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med. 2021 09; 9(9):999-1009.
Score: 0.060
-
A Unique SARS-CoV-2 Spike Protein P681H Variant Detected in Israel. Vaccines (Basel). 2021 Jun 08; 9(6).
Score: 0.059
-
Improved sensitivity, safety, and rapidity of COVID-19 tests by replacing viral storage solution with lysis buffer. PLoS One. 2021; 16(3):e0249149.
Score: 0.059
-
Absence of in-flight transmission of SARS-CoV-2 likely due to use of face masks on board. J Travel Med. 2020 12 23; 27(8).
Score: 0.058
-
Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis. PLoS One. 2020; 15(11):e0241164.
Score: 0.057
-
Characteristics of Clinically Asymptomatic Patients with SARS-CoV-2 Infections, Case Series. Prehosp Disaster Med. 2021 Feb; 36(1):125-128.
Score: 0.057
-
Characterization of human parainfluenza virus-3 circulating in Israel, 2012-2015. J Clin Virol. 2018 10; 107:19-24.
Score: 0.049
-
Seasonal Influenza Vaccine Effectiveness in Preventing Laboratory-Confirmed Influenza in Primary Care in Israel, 2016-2017 Season: Insights Into Novel Age-Specific Analysis. Clin Infect Dis. 2018 04 17; 66(9):1383-1391.
Score: 0.048
-
Effectiveness of influenza vaccine in preventing medically-attended influenza virus infection in primary care, Israel, influenza seasons 2014/15 and 2015/16. Euro Surveill. 2018 02; 23(7).
Score: 0.047